Related Experiment Video
Updated: Jul 13, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
A renaissance for YES in cancer
Marjorie Lapouge1, Sylvain Meloche2,3,4
1Institute for Research in Immunology and Cancer, Montreal, QC, Canada.
Abstract:
Most of our understanding regarding the involvement of SRC-family tyrosine kinases in cancer has stemmed from studies focused on the prototypical SRC oncogene. However, emerging research has shed light on the important role of YES signaling in oncogenic transformation, tumor growth, metastatic progression, and resistance to various cancer therapies. Clinical evidence indicates that dysregulated expression or activity of YES is a frequent occurrence in human cancers and is associated with unfavorable outcomes. These findings provide a compelling rationale for specifically targeting YES in certain cancer subtypes. Here, we review the crucial role of YES in cancer and discuss the challenges associated with translating preclinical observations into effective YES-targeted therapies.
Insights
Emerging research highlights the significant role of YES signaling in cancer development, progression, and treatment resistance. Targeting YES offers a promising therapeutic strategy for specific cancer subtypes, despite current challenges.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling
Background:
- SRC-family tyrosine kinases are crucial in cancer, with SRC being extensively studied.
- Emerging evidence implicates YES signaling in key oncogenic processes like transformation, tumor growth, metastasis, and therapy resistance.
Purpose of the Study:
- To review the critical role of YES signaling in cancer.
- To discuss the challenges in developing effective YES-targeted therapies.
Main Methods:
- Literature review of preclinical and clinical studies on YES signaling in cancer.
Main Results:
- Dysregulated YES expression/activity is common in human cancers.
- YES activity correlates with poor patient prognosis.
- YES signaling contributes to tumor growth, metastasis, and drug resistance.
Conclusions:
- YES is a significant factor in oncogenesis and cancer progression.
- Targeting YES presents a viable therapeutic avenue for specific cancers.
- Translating preclinical findings into clinical YES-targeted therapies faces challenges.
More Related Videos
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Related Concept Videos
Treatment Resistant Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...